2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 472

CCR6 Expression Regulates Arthritis in a T Cell Dependent Manner
Abstract Number: 179

CD11b+Gr1dimcells, Which Are Induced By GM-CSF Produced By Th17 and Group3 Innate Lymphoid Cell, May Facilitate the Progression of Pneumonitis in SKG Mice
Abstract Number: 2136

CD14 Deficiency Delays Progression of Cartilage Degeneration and Protects Against Early Deficits in Functional Outcomes in a Murine Osteoarthritis Model
Abstract Number: 2874

CD16+monocytes Are Enriched and Functionally Exacerbated in Driving B Cell Activation Under Systemic Lupus Erythematosus Condition
Abstract Number: 1822

CD4+ T Cell Lymphopenia Is Associated with Deficient Ubiquitination of the Cell Cycle Inhibibitor p27kip1 By the E3 Ligase Casitas B-Lineage Lymphoma-b in Patients with Systemic Lupus Erythematosus
Abstract Number: 2882

CD4+ T Helper Cells and Regulatory T Cells in Active Lupus Nephritis – an Imbalance Towards a Predominant Th1 Response?
Abstract Number: 1075

CD40-Pathway Activation in Ectopic Lymphoid Structure (ELS)-Resident B Cells Contributes to Disease Pathology in Primary SjöGren’s Syndrome
Abstract Number: 2421

Cell-Bound Complement Activation Products Correlate with Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 2800

Cell-Bound Complement Activation Products in Multi-Analyte Assay with Algorithm Aid the Diagnosis of Systemic Lupus Erythematosus
Abstract Number: 581

Cell-Mediated Neutrophil Lysis-a Mechanism Promoting Hypercitrullination in Rheumatoid Arthritis?
Abstract Number: 2884

Cell-Type Specific Epigenetic Features of Systemic Lupus Erythematosus
Abstract Number: 1197

Certain Serum Micro-RNAs Are Associated with Osteoarthritis
Abstract Number: 350

Change in Bone Mineral Density with High-Dose Prednisone in Patients with Rheumatoid Arthritis
Abstract Number: 2231

Change in Health Care Utilization after Etanercept Initiation in Patients with Rheumatoid Arthritis
Abstract Number: 2554

Changes in Blood Pressure Following the Initiation of Disease Modifying Therapies in US Veterans with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].